Physician profile
Andrew Graf
NPI 1316108269
$169,999.66
in general payments reported to CMS, 2019-2025
36 companies · $44.17 in 2025
The $44.17 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $2,633 · 2021: $39K · 2022: $37K · 2023: $38K · 2024: $6,800 · 2025: $44.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38K · Consulting Fee: $2,956 · Food and Beverage: $1,727 · Travel and Lodging: $1,396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38,381.20 |
| Consulting Fee | $2,956.25 |
| Food and Beverage | $1,726.59 |
| Travel and Lodging | $1,396.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $112,226.66 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $41,267.66 | 2020-2024 | Rexulti, Nuedexta |
| Janssen Pharmaceuticals, INC | $6,253.27 | 2019-2021 | |
| Urovant Sciences INC | $3,517.80 | 2022 | |
| Sumitomo Pharma America, INC. | $2,962.60 | 2023 | Gemtesa, Aptiom |
| Sunovion Pharmaceuticals INC. | $708.81 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $467.08 | 2019-2024 | Nuplazid |
| Novartis Pharmaceuticals Corporation | $329.05 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $294.18 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $281.56 | 2019-2025 | Austedo Xr, Austedo Xr |
| Ucb, INC. | $257.58 | 2019-2022 | |
| Pfizer INC. | $222.93 | 2019-2022 | |
| Astellas Pharma US INC | $213.72 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $173.78 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.05 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $101.14 | 2021 | |
| Sun Pharmaceutical Industries INC. | $98.35 | 2019-2021 | |
| Biogen, INC. | $80.00 | 2021 | |
| Lilly USA, LLC | $55.10 | 2020-2022 | |
| Amarin Pharma, INC. | $37.85 | 2019 | |
| Allergan, INC. | $37.05 | 2019-2020 | |
| Abbvie INC. | $36.99 | 2021 | |
| Inspire Medical Systems, INC. | $36.98 | 2024 | Inspire |
| Boston Scientific Corporation | $34.00 | 2020-2021 | |
| Axsome Therapeutics, INC. | $32.88 | 2023 | Sunosi |
| Acorda Therapeutics, INC | $22.25 | 2019 | |
| Nestle Healthcare Nutrition INC. | $18.71 | 2020 | |
| Mdd US Operations, LLC | $18.42 | 2020 | |
| Alexion Pharmaceuticals, INC. | $16.98 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.06 | 2021 | |
| Neurocrine Biosciences, INC. | $14.55 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.74 | 2019 | |
| Amphastar Pharmaceuticals, INC. | $13.04 | 2023 | Baqsimi |
| Smith+Nephew, INC. | $12.21 | 2021 | |
| Amgen INC. | $11.33 | 2021 | |
| Edw Pharma, INC. | $9.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Graf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.